Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone

Trial Profile

Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2012

At a glance

  • Drugs Tipranavir (Primary) ; Buprenorphine/naloxone; Ritonavir
  • Indications HIV infections; Opioid abuse
  • Focus Pharmacokinetics
  • Acronyms BUTI
  • Most Recent Events

    • 16 Dec 2007 Status changed from recruiting to completed.
    • 06 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top